254 related articles for article (PubMed ID: 28288656)
1. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
[TBL] [Abstract][Full Text] [Related]
2. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Daniyan AF; Brentjens RJ
J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor.
Wang Y; Gao Y; Niu C; Wang B; Zhao S; Roex G; Qian J; Qie J; Chen L; Yi C; Anguille S; Liu J; Luo F; Chu Y
Cancer Immunol Immunother; 2022 Nov; 71(11):2801-2814. PubMed ID: 35441325
[TBL] [Abstract][Full Text] [Related]
4. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.
Kamiya T; Wong D; Png YT; Campana D
Blood Adv; 2018 Mar; 2(5):517-528. PubMed ID: 29507075
[TBL] [Abstract][Full Text] [Related]
5. Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System.
Abudureheman T; Zhou H; Yang LT; Huang XS; Jing JJ; Duan CW; Chen KM
Bioconjug Chem; 2024 May; 35(5):604-615. PubMed ID: 38661725
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.
Hu W; Zi Z; Jin Y; Li G; Shao K; Cai Q; Ma X; Wei F
Cancer Immunol Immunother; 2019 Mar; 68(3):365-377. PubMed ID: 30523370
[TBL] [Abstract][Full Text] [Related]
7. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.
Barrett DM; Liu X; Jiang S; June CH; Grupp SA; Zhao Y
Hum Gene Ther; 2013 Aug; 24(8):717-27. PubMed ID: 23883116
[TBL] [Abstract][Full Text] [Related]
8. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.
Krug C; Birkholz K; Paulus A; Schwenkert M; Schmidt P; Hoffmann N; Hombach A; Fey G; Abken H; Schuler G; Schuler-Thurner B; Dörrie J; Schaft N
Cancer Immunol Immunother; 2015 Dec; 64(12):1623-35. PubMed ID: 26515978
[TBL] [Abstract][Full Text] [Related]
9. Rapid In Vitro Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging.
Subham S; Jeppson JD; Gibbs BK; Babai J; Alker R; Godwin AK; Akhavan D
J Vis Exp; 2023 Oct; (200):. PubMed ID: 37955379
[TBL] [Abstract][Full Text] [Related]
10. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.
Krug C; Wiesinger M; Abken H; Schuler-Thurner B; Schuler G; Dörrie J; Schaft N
Cancer Immunol Immunother; 2014 Oct; 63(10):999-1008. PubMed ID: 24938475
[TBL] [Abstract][Full Text] [Related]
11. A chimeric antigen receptor-based cellular safeguard mechanism for selective
Svec M; Dötsch S; Warmuth L; Trebo M; Fräßle S; Riddell SR; Jäger U; D'Ippolito E; Busch DH
Front Immunol; 2023; 14():1268698. PubMed ID: 38274808
[TBL] [Abstract][Full Text] [Related]
12. Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor T cells.
Zheng R; Chen Y; Zhang Y; Liang S; Zhao X; Wang Y; Wang P; Meng R; Yang A; Yan B
Front Immunol; 2023; 14():1258156. PubMed ID: 38022548
[TBL] [Abstract][Full Text] [Related]
13. [In vitro and in vivo validation of cytotoxicity of targeting human epidermal growth factor receptor-2 chimeric antigen receptor T (HER2-CAR-T) cells].
Zhang Y; Xi W; Wang P; Zhao X; Zheng R; Liang S; Meng R; Yan B; Yang A
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):289-295. PubMed ID: 38710512
[TBL] [Abstract][Full Text] [Related]
14. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.
Barrett DM; Singh N; Liu X; Jiang S; June CH; Grupp SA; Zhao Y
Cytotherapy; 2014 May; 16(5):619-30. PubMed ID: 24439255
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory CARs fail to protect from immediate T cell cytotoxicity.
Funk MA; Heller G; Waidhofer-Söllner P; Leitner J; Steinberger P
Mol Ther; 2024 Apr; 32(4):982-999. PubMed ID: 38384128
[TBL] [Abstract][Full Text] [Related]
16. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.
Riberdy JM; Zhou S; Zheng F; Kim YI; Moore J; Vaidya A; Throm RE; Sykes A; Sahr N; Bonifant CL; Ryu B; Gottschalk S; Velasquez MP
Mol Ther Methods Clin Dev; 2020 Sep; 18():571-581. PubMed ID: 32775492
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Drent E; Poels R; Mulders MJ; van de Donk NWCJ; Themeli M; Lokhorst HM; Mutis T
PLoS One; 2018; 13(5):e0197349. PubMed ID: 29847570
[TBL] [Abstract][Full Text] [Related]
18. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells.
Li S; Wang CS; Montel-Hagen A; Chen HC; Lopez S; Zhou O; Dai K; Tsai S; Satyadi W; Botero C; Wong C; Casero D; Crooks GM; Seet CS
Cell Rep; 2023 Mar; 42(3):112241. PubMed ID: 36906850
[TBL] [Abstract][Full Text] [Related]
19. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
20. Magnetic CAR T cell purification using an anti-G4S linker antibody.
Harrer DC; Li SS; Kaljanac M; Bezler V; Barden M; Pan H; Herr W; Abken H
J Immunol Methods; 2024 May; 528():113667. PubMed ID: 38574803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
